Research and Clinical Trials
The following organizations are currently doing research on APS or related diseases. We encourage anyone who qualifies to participate in these clinical studies. By doing so, you could potentially help APS patients in the future!
Antiphospholipid Syndrome Research Labs
Principal Investigator:
Dr. Jason Knight
Michigan Medicine, Ann Arbor, MI
Contact:
BASIC RESEARCH
Sri Yalavarthi, MS
syalavar@med.umich.edu
734-615-1880
CLINICAL RESEARCH
Claire Hoy, BS
MichiganANSWERS@med.umich.edu
734-647-3949
Please visit the Antiphospholipid Syndrome Program section on UofMHealth.org to learn about APS and how to make an appointment at their clinic. The team at Michigan Medicine is working to advance the understanding of the disease process and identify new, sophisticated approaches to the treatment of APS that are both personalized and proactive. The latest information about clinical trials can be found on their website.
APS ACTION Hydroxychloroquine Study (1)
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*
Contact:
Joann Vega
(212) 774-2795
aPL-positive patients with no history of thrombosis or other systemic autoimmune diseases are randomized to receive hydroxychloroquine or no treatment in addition to their standard regimen. The study involves 11 study visits and 10 phone visits over 5 years.
APS ACTION aPL/APS Registry (2)
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*
Contact:
Joann Vega
(212) 774-2795
Any aPL-positive patient is included in this clinical database and repository. The study involves 11 study visits and 10 phone visits over 10 years.
Microbiome Study (3)
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY
Contact:
Joann Vega
(212) 774-2795
aPL-positive patients who are not receiving immunosuppressive treatment is included in this study that seeks to find if any particular intestinal bacteria may trigger aPL production. Participation will involve 3 study visits over a period of 2 months
PROMISSE Study (4)
Dr. Jane Salmon
Hospital for Special Surgery, New York, NY*
Contact:
Anasam Aslam
(212) 774-2115
Pregnant (6-11 weeks preferably, but can usually recruit up to 18 weeks), history of aPL positivity with or without SLE.
AXLN1007 in Antiphospholipid Syndrome (5)
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*
Contact:
Joann Vega
(212) 774-2795
Study Title: An Open-Label Proof of Concept Phase IIa Trial of AXLN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
This is an open-label study where patients will receive 12 doses of study drug over 22 weeks for Non-criteria Manifestations of APS (low platelet count, skin ulcers or abnormal kidney function).
Navigate through Current Clinical Trials using the left and right arrows.
DARE-APS: a new clinical trial
DARE-APS: a new clinical trial
DARE-APS, a new clinical trial investigating the safety of the drug Darzalex® (daratumumab) in patients with antiphospholipid syndrome (APS) is now open for enrollment at two study sites.
See https://www.dare-aps.org for more information
Our Mission
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.
Information Sheets
DISCLAIMER: The APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your doctor. Always seek a trained physician's advice before seeking any new treatment regarding your medical diagnosis or condition. Any information received from the APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will list all donors' or purchasers' names on the donor page of our foundation site. If you do not want your name listed, please get in touch with us to opt-out. If you think you may have a medical emergency, call your doctor or 911 immediately.
Seeking Participants: Pregnancy and Antiphospholipid Syndrome (APS) Study
Seeking Participants: Pregnancy and Antiphospholipid Syndrome (APS) Study
WHO: We are looking for people who have primary APS, are 18-45 years old, and have been or are considering becoming pregnant. You are eligible if you have ever been pregnant, regardless of how the pregnancy ended (such as miscarriage/stillbirth, live birth, abortion).
WHY: To help us understand the experiences, priorities, and concerns surrounding pregnancy for individuals with APS
WHAT: Online survey and potentially a Zoom interview
HOW: Fill out your contact information using this link or the QR code below so we can follow up with you
Email: APSresearch@umich.edu
Alexandra Harper, PhD, OTR/L, CPHQ
Jason Knight, MD, PhD
Susan Murphy, ScD, OTR
Justine Wu, MD, MPH
Our Mission
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.
Information Sheets
DISCLAIMER: The APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your doctor. Always seek a trained physician's advice before seeking any new treatment regarding your medical diagnosis or condition. Any information received from the APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will list all donors' or purchasers' names on the donor page of our foundation site. If you do not want your name listed, please get in touch with us to opt-out. If you think you may have a medical emergency, call your doctor or 911 immediately.
COVID19
COVID-19
Our Mission
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.
Information Sheets
DISCLAIMER: The APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your doctor. Always seek a trained physician's advice before seeking any new treatment regarding your medical diagnosis or condition. Any information received from the APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will list all donors' or purchasers' names on the donor page of our foundation site. If you do not want your name listed, please get in touch with us to opt-out. If you think you may have a medical emergency, call your doctor or 911 immediately.
If You Have Antiphospholipid Syndrome (APS) And Lupus, You May Qualify For A Research Study
If You Have Antiphospholipid Syndrome (APS) And Lupus, You May Qualify For A Research Study
The Paisley Study is a research study that is evaluating an oral investigational drug for people with moderate to severe systemic lupus erythematosus (SLE). Qualified participants must be on stable anticoagulant therapy as long as APS is not the sole or predominant feature of their SLE.
Visit PaisleyStudy.com to learn more today.
Rare Diseases Clinical Research Network
The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease risk, disease severity and activity, and clinical outcome, while also encouraging development of new approaches to diagnosis, prevention, and treatment.
For more information, visit rarediseasesnetwork.org.
Clinical Study: PROMISSE
NOW RECRUITING
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE)
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.
More Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00198068
Contact:
Marta M. Guerra, MS
212-774-7361
guerram@hss.edu
Clinical Study: Genetic Risk Factors Associated With APS
NOW RECRUITING
Genetic Risk Factors Associated With Antiphospholipid Syndrome (APS)
Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body’s ability to perform normal blood clotting. Clinical problems associated with antiphospholipid antibodies include an increased risk for the formation of blood clots in the lungs or deep veins of the legs, stroke, heart attack, and recurrent miscarriages. It is possible that some people with APS have a genetic predisposition for developing the syndrome. This study will use a genetic strategy to identify potential inherited risk factors for the development of APS by recruiting people with APS who have family members also affected by the syndrome or by another autoimmune disorder, such as lupus or rheumatoid arthritis.
More Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00482794
APS ACTION
The primary mission of APS ACTION is to prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research. Their secondary mission is to refine and advance the definitions of aPL associated clinical manifestations through international collaboration and data sharing.
Their approach is simple: Members will work together to create a research alliance that will design and conduct clinical trials, and collect data via an international registry.
For more information, visit apsaction.org.
Our Mission
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.
Information Sheets
DISCLAIMER: The APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your doctor. Always seek a trained physician's advice before seeking any new treatment regarding your medical diagnosis or condition. Any information received from the APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will list all donors' or purchasers' names on the donor page of our foundation site. If you do not want your name listed, please get in touch with us to opt-out. If you think you may have a medical emergency, call your doctor or 911 immediately.